Fernandez F M, Conner M E, Hodgins D C, Parwani A V, Nielsen P R, Crawford S E, Estes M K, Saif L J
Food Animal Health Research Program, Ohio Agricultural Research and Development Center, Ohio State University, Wooster 44691, USA.
Vaccine. 1998 Mar;16(5):507-16. doi: 10.1016/s0264-410x(97)80004-7.
Heterotypic passive immunity to IND (P/5/G6) bovine rotavirus (BRV) was evaluated. Three groups of calves (n = 5 per group) were fed 1% pooled colostrum supplements (birth to 7 days of age) from BRV seropositive cows vaccinated with recombinant SA11(P/2/G3) rotavirus-like particles (VLPs), recombinant SA11 rotavirus core-like particles (CLPs), or inactivated SA11 rotavirus (SA11). Control calves (n = 5 per group) received either pooled colostrum from unvaccinated (BRV field exposure seropositive) control cows, or no colostrum. IgG1 antibody titers to IND BRV for the pooled colostrum were: 1,048,576 (VLP); 1,048,576 (CLP); 262,144 (SA11); and 16,384 (control colostrum). Elevated titers of BRV neutralizing (VN) antibodies were present in VLP colostrum (98,000), and SA11 colostrum (25,000), but not in CLP colostrum (1400), compared to colostrum from nonvaccinates (2081). Calves were orally inoculated with virulent IND BRV at 2 days of age and challenged at post-inoculation day (PID) 21. Calves were monitored daily for diarrhea and faecal BRV shedding through PID 10 and post-challenge day (PCD) 10. After colostrum feeding, the IgG1 antibody titers were highest in serum and faeces of calves fed VLP and CLP colostrum, but VN and IgA antibodies were highest in calves fed VLP colostrum. After BRV inoculation, calves fed colostrum from vaccinated cows had significantly fewer days of BRV-associated diarrhea and BRV shedding than control calves. All calves fed VLP colostrum were protected from diarrhea after BRV inoculation; two calves shed BRV. In the CLP colostrum group, one calf developed BRV-associated diarrhea and all calves shed virus. In the SA11 colostrum group, three calves developed BRV-associated diarrhea and four calves shed virus. BRV-associated diarrhea and shedding occurred in 9 of 10 control calves. Active IgM antibody responses occurred in faeces and/or serum of most calves after BRV inoculation. However, the highest active antibody responses (IgM and IgG1 in serum, and IgM, IgG1 or IgA in faeces) after BRV inoculation were in calves fed control or no colostrum, in association with clinical diarrhea in most of these calves. After challenge at PID 21, BRV-associated diarrhea and shedding were of short duration or absent, in all groups. These results demonstrate the efficacy of colostrum from VLP vaccinated cows to provide heterologous, passive protection against BRV diarrhea and shedding in calves. In comparison, calves fed CLP or SA11 colostrum were only partially protected against BRV diarrhea or shedding.
评估了对印第安纳州(P/5/G6)牛轮状病毒(BRV)的异型被动免疫。三组犊牛(每组n = 5头)在出生至7日龄期间喂食了来自接种重组SA11(P/2/G3)轮状病毒样颗粒(VLP)、重组SA11轮状病毒核心样颗粒(CLP)或灭活SA11轮状病毒(SA11)的BRV血清阳性奶牛的1%混合初乳补充剂。对照犊牛(每组n = 5头)接受来自未接种(BRV野外暴露血清阳性)对照奶牛的混合初乳,或不接受初乳。混合初乳针对印第安纳州BRV的IgG1抗体滴度分别为:1,048,576(VLP);1,048,576(CLP);262,144(SA11);以及16,384(对照初乳)。与未接种疫苗奶牛的初乳(2081)相比,VLP初乳(98,000)和SA11初乳(25,000)中存在较高滴度的BRV中和(VN)抗体,但CLP初乳(1400)中没有。犊牛在2日龄时口服接种强毒印第安纳州BRV,并在接种后天数(PID)21进行攻毒。每天监测犊牛直至PID 10和攻毒后天数(PCD)10的腹泻情况和粪便中BRV的排出。初乳喂养后,喂食VLP和CLP初乳的犊牛血清和粪便中的IgG1抗体滴度最高,但VN和IgA抗体在喂食VLP初乳的犊牛中最高。BRV接种后,喂食接种疫苗奶牛初乳的犊牛与BRV相关的腹泻天数和BRV排出天数明显少于对照犊牛。所有喂食VLP初乳的犊牛在BRV接种后都免受腹泻影响;两头犊牛排出BRV。在CLP初乳组中,一头犊牛出现BRV相关腹泻,所有犊牛都排出病毒。在SA11初乳组中,三头犊牛出现BRV相关腹泻,四头犊牛排出病毒。10头对照犊牛中有9头出现BRV相关腹泻和病毒排出。大多数犊牛在BRV接种后粪便和/或血清中出现活性IgM抗体反应。然而,BRV接种后最高的活性抗体反应(血清中的IgM和IgG1,以及粪便中的IgM、IgG1或IgA)出现在喂食对照初乳或未喂食初乳的犊牛中,且这些犊牛中的大多数伴有临床腹泻。在PID 21攻毒后,所有组中与BRV相关的腹泻和病毒排出持续时间短或未出现。这些结果证明了来自接种VLP奶牛的初乳对犊牛提供针对BRV腹泻和病毒排出的异源被动保护的有效性。相比之下,喂食CLP或SA11初乳的犊牛仅部分免受BRV腹泻或病毒排出的影响。